John Spaid L.'s Insider Trades & SAST Disclosures
John Spaid L.'s most recent trade in National Health Investors, Inc. was a trade of 15,000 Stock Option (Right to Buy) 2025 done . Disclosure was reported to the exchange on March 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern John Spaid L..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) 2025 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) 2025 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) 2025 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 6,500 | 44,682 (0%) | 0% | 0 | Common Stock | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.96 per share. | 23 Feb 2025 | 267 | 38,182 (0%) | 0% | 69.0 | 18,412 | Common Stock |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.43 per share. | 03 Sep 2024 | 49,637 | 38,449 (0%) | 0% | 81.4 | 4,041,941 | Common Stock |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.41 per share. | 03 Sep 2024 | 18,333 | 62,585 (0%) | 0% | 53.4 | 979,166 | Common Stock |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.41 per share. | 03 Sep 2024 | 18,333 | 44,252 (0%) | 0% | 53.4 | 979,166 | Common Stock |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 18,333 | 0 | - | - | Stock Option (Right to buy) 2022 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 18,333 | 0 | - | - | Stock Option (Right to buy) 2022 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.76 per share. | 03 Sep 2024 | 8,500 | 88,086 (0%) | 0% | 57.8 | 490,960 | Common Stock |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.73 per share. | 03 Sep 2024 | 8,500 | 79,586 (0%) | 0% | 54.7 | 465,205 | Common Stock |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.73 per share. | 03 Sep 2024 | 8,500 | 71,086 (0%) | 0% | 54.7 | 465,205 | Common Stock |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 8,500 | 0 | - | - | Stock Option (Right to Buy) 2023 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 8,500 | 0 | - | - | Stock Option (Right to Buy) 2024 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 8,500 | 0 | - | - | Stock Option (Right to Buy) 2023 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.00 per share. | 03 Sep 2024 | 1 | 62,586 (0%) | 0% | 53 | 53 | Common Stock |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 1 | 0 | - | - | Stock Option (Right to buy) 2022 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.63 per share. | 23 Aug 2024 | 65,463 | 25,919 (0%) | 0% | 78.6 | 5,147,356 | Common Stock |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2024 | 18,334 | 0 | - | - | Stock Options (Right to Buy) 2-25-2021 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 69.20 per share. | 23 Aug 2024 | 18,334 | 73,049 (0%) | 0% | 69.2 | 1,268,713 | Common Stock |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2024 | 18,333 | 1 | - | - | Stock Option (Right to buy) 2022 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2024 | 18,333 | 0 | - | - | Stock Options (Right to Buy) 2-25-2021 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2024 | 18,333 | 0 | - | - | Stock Options (Right to Buy) 2-25-2021 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.41 per share. | 23 Aug 2024 | 18,333 | 91,382 (0%) | 0% | 53.4 | 979,166 | Common Stock |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 69.20 per share. | 23 Aug 2024 | 18,333 | 54,715 (0%) | 0% | 69.2 | 1,268,644 | Common Stock |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 69.20 per share. | 23 Aug 2024 | 18,333 | 36,382 (0%) | 0% | 69.2 | 1,268,644 | Common Stock |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 64.72 per share. | 06 May 2024 | 230 | 18,049 (0%) | 0% | 64.7 | 14,886 | Common Stock |
| National Health Investors,... | L. Spaid John | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 8,500 | 8,500 | - | - | Stock Option (Right to Buy) 2024 | |
| National Health Investors,... | John Spaid L. | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 8,500 | 8,500 | - | - | Stock Option (Right to Buy) 2024 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 8,500 | 8,500 | - | - | Stock Option (Right to Buy) 2024 | |
| National Health Investors,... | L. John Spaid | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 3,000 | 18,279 (0%) | 0% | 0 | Common Stock | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 4,000 | 15,279 (0%) | 0% | 0 | Common Stock | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 8,500 | 8,500 | - | - | Stock Option (Right to Buy) 2023 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 8,500 | 8,500 | - | - | Stock Option (Right to Buy) 2023 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 8,500 | 8,500 | - | - | Stock Option (Right to Buy) 2023 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 18,334 | 18,334 | - | - | Stock Option (Right to buy) 2022 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 18,333 | 18,333 | - | - | Stock Option (Right to buy) 2022 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 18,333 | 18,333 | - | - | Stock Option (Right to buy) 2022 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 18,334 | 18,334 | - | - | Stock Options (Right to Buy) 2-25-2021 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 18,333 | 18,333 | - | - | Stock Options (Right to Buy) 2-25-2021 | |
| National Health Investors,... | John L. Spaid | CFO/EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 18,333 | 18,333 | - | - | Stock Options (Right to Buy) 2-25-2021 |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges